PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops and markets innovative, stable oxychlorine compounds based on the Microcyn® Technology platform that are intended to treat a wide range of infections, including those in chronic and acute wounds, announced that the company will participate in the Third Congress of the World Union of Wound Healing Societies being held in Toronto, Ontario on June 4-8, 2008.
